L. 'obésité-est-un-facteur-de-mauvais-pronostic-dans-le-cancer-du-sein and .. , 24 II. Les traitements systémiques adjuvants dans le cancer du sein, p.25

F. Toxicités-du, Tableau n°1), p.34

D. Toxicités, Tableau n°2), p.36

.. Mesure-des-plis-cutanés, 44 L'impédancemétrie bioélectrique 45 L'absorptiométrie biphotonique à rayons X (DEXA), p.46

). Modalités-de-la-chimiothérapie-reçue-tableau-n°6, 60 II. Toxicités objectives de, p.61

A. H. Mokdad, The Spread of the Obesity Epidemic in the United States, 1991-1998, JAMA, vol.282, issue.16, pp.1519-1541, 1991.
DOI : 10.1001/jama.282.16.1519

A. G. Renehan, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, The Lancet, vol.371, issue.9612, pp.371-569, 2008.
DOI : 10.1016/S0140-6736(08)60269-X

A. Bergstrom, Overweight as an avoidable cause of cancer in Europe

A. Trentham-dietz, Body Size and Risk of Breast Cancer, American Journal of Epidemiology, vol.145, issue.11, pp.145-1011, 1997.
DOI : 10.1093/oxfordjournals.aje.a009057

G. Ursin, A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology, pp.137-178, 1995.

G. Berclaz, Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience, Annals of Oncology, vol.15, issue.6, pp.15-875, 2004.
DOI : 10.1093/annonc/mdh222

G. Bonadonna, Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience, Recent Results Cancer Res, vol.80, pp.149-56, 1982.
DOI : 10.1007/978-3-642-81685-7_25

R. Peto, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, issue.9814, pp.379-432, 2012.

H. Roche, Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, Journal of Clinical Oncology, vol.24, issue.36
DOI : 10.1200/JCO.2006.07.3916

G. A. Viani, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials, BMC Cancer, vol.20, issue.suppl 1, p.153, 2007.
DOI : 10.1200/JCO.20.5.1215

C. Jacquillat, Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer, Cancer, vol.8, issue.1, pp.119-148, 1990.
DOI : 10.1002/1097-0142(19900701)66:1<119::AID-CNCR2820660122>3.0.CO;2-3

G. Bonadonna, Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute., Journal of Clinical Oncology, vol.16, issue.1, pp.93-100, 1998.
DOI : 10.1200/JCO.1998.16.1.93

P. Chollet, Clinical and pathological response to primary chemotherapy in operable breast cancer, European Journal of Cancer, vol.33, issue.6, pp.862-868, 1997.
DOI : 10.1016/S0959-8049(97)00038-5

B. Fisher, Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18., Journal of Clinical Oncology, vol.15, issue.7, pp.2483-93, 1997.
DOI : 10.1200/JCO.1997.15.7.2483

H. D. Bear, Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol, issue.13, pp.24-2019, 2006.

G. Lazaridis, G. Pentheroudakis, and N. Pavlidis, Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety, Critical Reviews in Oncology/Hematology, vol.66, issue.1, pp.31-41, 2008.
DOI : 10.1016/j.critrevonc.2007.07.002

P. Kerbrat, Epirubicin???vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial, British Journal of Cancer, vol.13, issue.11, pp.96-1633, 2007.
DOI : 10.1200/JCO.2005.10.517

G. Brufman, Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group, Annals of Oncology, vol.8, issue.2, pp.155-62, 1997.
DOI : 10.1023/A:1008295427877

P. Fumoleau, A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC, Annals of Oncology, vol.7, issue.2, pp.165-71, 1996.
DOI : 10.1093/oxfordjournals.annonc.a010544

B. Chevallier, Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer., Journal of Clinical Oncology, vol.13, issue.2, pp.314-336, 1995.
DOI : 10.1200/JCO.1995.13.2.314

O. 'brien and M. E. , Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group, Annals of Oncology, vol.10, issue.2, pp.205-215, 1999.
DOI : 10.1023/A:1008370930599

J. Bonneterre, Efficacy and safety of docetaxel (Taxotere???) in heavily pretreated advanced breast cancer patients, European Journal of Cancer, vol.35, issue.10, pp.35-1431, 1999.
DOI : 10.1016/S0959-8049(99)00174-4

P. Jenkins, S. Elyan, and S. Freeman, Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer, European Journal of Cancer, vol.43, issue.3, pp.43-544, 2007.
DOI : 10.1016/j.ejca.2006.10.013

G. L. Rosner, Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541., Journal of Clinical Oncology, vol.14, issue.11, pp.14-3000, 1996.
DOI : 10.1200/JCO.1996.14.11.3000

M. Colleoni, Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index, The Lancet, vol.366, issue.9491, pp.1108-1118, 2005.
DOI : 10.1016/S0140-6736(05)67110-3

P. Poikonen, C. Blomqvist, and H. Joensuu, Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area, Acta Oncol, vol.40, issue.1, pp.67-71, 2001.

A. Felici, J. Verweij, and A. Sparreboom, Dosing strategies for anticancer drugs: the good, the bad and body-surface area, European Journal of Cancer, vol.38, issue.13, pp.38-1677, 2002.
DOI : 10.1016/S0959-8049(02)00151-X

B. Desoize, [To which criterion should the dosage of anticancer drug be adapted?], Bull Cancer, vol.80, issue.5, pp.376-90, 1993.

J. M. Ferrero, The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer, Cancer Chemotherapy and Pharmacology, vol.50, issue.6, pp.50-459, 2002.
DOI : 10.1007/s00280-002-0519-2

D. Bois, D. , and E. F. Bois, A formula to estimate the approximate surface area if height and weight be known, Nutrition, vol.5, issue.5, pp.303-314, 1916.

E. J. Freireich, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man, Cancer Chemother Rep, vol.50, issue.4, pp.219-263, 1966.

E. R. Homan, Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man, Cancer Chemother Rep, vol.3, issue.31, pp.13-22, 1972.

S. D. Baker, L. B. Grochow, and R. C. Donehower, Should Anticancer Drug Doses Be Adjusted in the Obese Patient?, JNCI Journal of the National Cancer Institute, vol.87, issue.5, pp.333-337, 1995.
DOI : 10.1093/jnci/87.5.333

R. H. Mathijssen, Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?, The Oncologist, vol.12, issue.8, pp.12-913, 2007.
DOI : 10.1634/theoncologist.12-8-913

R. Jain, Implications of Obesity for Drug Therapy: Limitations and Challenges, Clinical Pharmacology & Therapeutics, vol.37, issue.1, pp.77-89, 2011.
DOI : 10.1038/sj.ijo.0801555

B. Green and S. B. , What is the best size descriptor to use for pharmacokinetic studies in the obese?, British Journal of Clinical Pharmacology, vol.42, issue.2, pp.119-152, 2004.
DOI : 10.1097/00000542-200301000-00014

R. J. Hunter, Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA), Cancer Treatment Reviews, vol.35, issue.1, pp.69-78, 2009.
DOI : 10.1016/j.ctrv.2008.07.005

J. J. Griggs, M. E. Sorbero, and G. H. Lyman, Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy, Archives of Internal Medicine, vol.165, issue.11, pp.165-1267, 2005.
DOI : 10.1001/archinte.165.11.1267

M. J. Peterson, S. A. Czerwinski, and R. M. Siervogel, Development and validation of skinfold-thickness prediction equations with a 4-compartment model, Am J Clin Nutr, issue.5, pp.77-1186, 2003.

J. Brozek, DENSITOMETRIC ANALYSIS OF BODY COMPOSITION: REVISION OF SOME QUANTITATIVE ASSUMPTIONS*, Annals of the New York Academy of Sciences, vol.10, issue.Suppl. 126, pp.113-153, 1963.
DOI : 10.1111/j.1749-6632.1963.tb17079.x

L. B. Houtkooper, Why bioelectrical impedance analysis should be used for estimating adiposity, Am J Clin Nutr, vol.64, issue.3, pp.436-448, 1996.

N. Mitsiopoulos, Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol, vol.85, issue.1, pp.115-137, 1998.

M. Mourtzakis, A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Applied Physiology, Nutrition, and Metabolism, vol.33, issue.5, pp.997-1006, 2008.
DOI : 10.1139/H08-075

W. Shen, Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, Journal of Applied Physiology, vol.97, issue.6, pp.97-2333, 2004.
DOI : 10.1152/japplphysiol.00744.2004

C. M. Prado, Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity, Clinical Cancer Research, vol.13, issue.11, pp.13-3264, 2007.
DOI : 10.1158/1078-0432.CCR-06-3067

C. M. Prado, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, The Lancet Oncology, vol.9, issue.7, pp.629-664, 2008.
DOI : 10.1016/S1470-2045(08)70153-0

M. S. Aapro, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, European Journal of Cancer, vol.42, issue.15, pp.42-2433, 2006.
DOI : 10.1016/j.ejca.2006.05.002

J. D. Rizzo, Use of epoetin and darbepoetin in patients with cancer, 2007.

J. D. Rizzo, American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, American Society of Clinical Oncology J Clin Oncol, issue.33, pp.28-4996, 2010.

S. Dawood, Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer, Clinical Cancer Research, vol.14, issue.6, pp.1718-1743, 2008.
DOI : 10.1158/1078-0432.CCR-07-1479

S. Chang, A. U. Buzdar, and S. D. Hursting, Inflammatory breast cancer and body mass index., Journal of Clinical Oncology, vol.16, issue.12, pp.16-3731, 1998.
DOI : 10.1200/JCO.1998.16.12.3731

P. Fumoleau, Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results, Annals of Oncology, vol.17, issue.1, pp.85-92, 2006.
DOI : 10.1093/annonc/mdj034

J. J. Griggs, Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, issue.13, pp.30-1553, 2012.

A. Degen, The hand-foot-syndrome associated with medical tumor therapy - classification and management, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, vol.74, issue.Suppl 1, pp.652-61, 2010.
DOI : 10.1111/j.1610-0387.2010.07449.x

E. H. Livingston and S. Lee, Body surface area prediction in normal-weight and obese patients, Am J Physiol Endocrinol Metab, vol.281, issue.3, pp.586-91, 2001.

J. Verbraecken, Body surface area in normal-weight, overweight, and obese adults. A comparison study, Metabolism, vol.55, issue.4, pp.515-539, 2006.
DOI : 10.1016/j.metabol.2005.11.004

R. Bruno, Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer., Journal of Clinical Oncology, vol.16, issue.1, pp.187-96, 1998.
DOI : 10.1200/JCO.1998.16.1.187

A. Sparreboom, Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese, Journal of Clinical Oncology, vol.25, issue.30, pp.25-4707, 2007.
DOI : 10.1200/JCO.2007.11.2938

D. J. Morgan and K. M. Bray, Lean Body Mass as a Predictor of Drug Dosage, Clinical Pharmacokinetics, vol.26, issue.4, pp.292-307, 1994.
DOI : 10.2165/00003088-199426040-00005

G. T. Sucak, The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan???cyclophosphamide conditioning, International Journal of Hematology, vol.102, issue.1, pp.95-101, 2012.
DOI : 10.1007/s12185-011-0980-y

M. J. Hanley, D. R. Abernethy, and D. J. Greenblatt, Effect of Obesity on the Pharmacokinetics of Drugs in Humans, Clinical Pharmacokinetics, vol.16, issue.5 Pt 1, pp.71-87, 2010.
DOI : 10.2165/11318100-000000000-00000

R. A. Blouin and G. W. Warren, Pharmacokinetic Considerations in Obesity, Journal of Pharmaceutical Sciences, vol.88, issue.1, pp.1-7, 1999.
DOI : 10.1021/js980173a

G. Cheymol, Clinical pharmacokinetics of drugs in obesity. An update, ): p. 103-14. 92 68. Les sources de variabilité de la réponse au médicament : Variabilités pharmacocinétiques ? Populations pathologiques particulières, 1993.

C. M. Prado, Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment, Clinical Cancer Research, vol.15, issue.8, pp.15-2920, 2009.
DOI : 10.1158/1078-0432.CCR-08-2242

F. Marre, Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans, Cancer Res, vol.56, issue.6, pp.1296-302, 1996.

M. Shou, Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver, Pharmacogenetics, vol.8, issue.5, pp.391-401, 1998.
DOI : 10.1097/00008571-199810000-00004

J. Hirth, The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance, Clin Cancer Res, vol.6, issue.4, pp.1255-1263, 2000.

M. Kotlyar and S. W. Carson, Effects of obesity on the cytochrome P450 enzyme system, Int J Clin Pharmacol Ther, vol.37, issue.1, pp.8-19, 1999.

S. D. Baker, Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients, Clinical Cancer Research, vol.10, issue.24, pp.8341-50, 2004.
DOI : 10.1158/1078-0432.CCR-04-1371

M. Marty, Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology, vol.23, issue.19, pp.23-4265, 2005.
DOI : 10.1200/JCO.2005.04.173

H. Joensuu, Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, pp.809-829, 2006.
DOI : 10.1056/NEJMoa053028

D. Slamon, Adjuvant Trastuzumab in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.365, issue.14, pp.1273-83, 2011.
DOI : 10.1056/NEJMoa0910383

S. E. Singletary, Revision of the American Joint Committee on Cancer Staging System for Breast Cancer, Journal of Clinical Oncology, vol.20, issue.17, pp.3628-3664, 2002.
DOI : 10.1200/JCO.2002.02.026

A. Hb and <. , 5 g/dL<Hb <8 g/dL Hb<6